
Issue Brief

FEDERAL ISSUE BRIEF



Analysis provided for MHA by Larry Goldberg, Goldberg Consulting

September 14, 2023

CMS to Reduce Coinsurance for Certain Part B Rebatable Drugs

One aspect of the ***Inflation Reduction Act of 2022*** requires drug companies to pay rebates to Medicare when prescription drug prices increase faster than the rate of inflation. This new inflation rebate applies to Medicare Part B rebatable drugs, which are single source drugs and biological products, including certain biosimilar biological products, beginning January 1, 2023.

CMS has identified 34 drugs that have drug prices increasing faster than the rate of inflation. CMS intends to invoice drug manufacturers for 2023 and 2024 Part B inflation rebates no later than fall 2025. The rebates will be deposited into the Medicare Trust Fund.

Beginning April 1, 2023, people with Medicare may see lower out-of-pocket costs for certain Part B drugs and biologicals with prices that have increased faster than the rate of inflation. For these drugs and biologicals, the beneficiary coinsurance will be 20 percent of the inflation-adjusted payment amount, which will be less than what the beneficiary would pay in coinsurance otherwise.

Individuals with traditional Medicare and Medicare Advantage who use these drugs may, depending on other health coverage they may have, pay a reduced amount for their coinsurance during this specific quarter. For the quarter, October 1 – December 31, people with Medicare may experience coinsurance amounts that are lower than what they would have paid before the new law passed by as much as \$1 - \$618 per average dose.

CMS' normal procedure is to release the Medicare Part B Quarterly Sales Pricing (ASP) files several weeks before the quarter they will go into effect so the public can review and notify CMS of any potential discrepancies. From time to time, ASP public files need to be corrected or updated, generally referred to as a restatement, based on feedback received after the files are published. If CMS receives feedback that necessitates updates to this list of drugs with adjusted coinsurance amounts, CMS will update the list.

The October 1 – December 31, 2023 files may be subject to updates either before the start of the quarter or after in the event updated data becomes available. Below is the list of 34 drugs with adjusted coinsurance amounts for the quarter October 1 – December 31, 2023.

HCPCS	Drug name	Inflation-Adjusted Coinsurance Percentage(Normally 20.000%)
J9042	ADCETRIS	19.754%
J3246	AGGRASTAT	19.698%
J8655	AKYNZEO	17.996%
J7504	ATGAM	16.834%
J0558	BICILLIN CR	17.741%
J0561	BICILLIN L-A	17.484%
J9039	BLINCYTO	19.517%
J2850	CHIRHOSTIM	19.328%
J1833	CRESEMBA	19.997%
J0584	CRYSVITA	19.744%
J1645	FRAGMIN	13.158%
J0135	HUMIRA	19.997%
J1670	HYPERTET	19.207%
J9325	IMLYGIC	19.772%
J9198	INFUGEM	19.669%
J2820	LEUKINE	19.711%
J1950	LUPRON DEPOT-PED	19.895%
J2265	MINOCIN	18.828%
J9268	NIPENT	19.562%
J2796	NPLATE	19.935%
J9266	ONCASPAR	19.382%
J9177	PADCEV	19.229%
J1640	PANHEMATIN	19.536%
J9314	PEMETREXED	13.634%
J9318	ROMIDEPSIN	19.509%
J9061	RYBREVANT	19.908%
J2502	SIGNIFOR LAR	17.881%
C9482	SOTALOL	19.729%
J2860	SYLVANT	18.984%
J9262	SYNRIBO	19.378%
J2186	VABOMERE	19.554%
J9303	VECTIBIX	19.921%
J0775	XIAFLEX	18.626%
J0291	ZEMDRI	19.739%

Questions? Contact Andrew Wheeler, MHA's Vice President of Federal Finance, at 573-893-3700 | ext. 1336 or awheeler@mhanet.com.

4712 Country Club Drive, Jefferson City, Mo. 65109
P.O. Box 60, Jefferson City, Mo. 65102
573/893-3700 | www.mhanet.com

